Medical Drug Clinical Criteria

Subject:	Yeztugo (lenacapavir)		
Document #:	CC-0289	**Publish Date:**	09/03/2025
Status:	New	**Last Review Date:**	08/15/2025

Table of Contents

Overview | Coding | References

Clinical Criteria | Document History

Overview

This document addresses the use of Yeztugo (lenacapavir), a human immunodeficiency virus (HIV) capsid inhibitor approved by the Food and Drug Administration (FDA) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV infection in adults and adolescents weighing at least 35 kg who are at risk for HIV acquisition. Individuals must have a negative HIV test prior to initiation of Yeztugo.

Yeztugo has a black box warning for risk of drug resistance when used in individuals with undiagnosed HIV infection. Individuals must be tested for HIV infection prior to initiating Yeztugo and with each subsequent injection of Yeztugo. Drug-resistant HIV variants have been identified with use of Yeztugo in individuals with undiagnosed HIV infection. Individuals who become infected with HIV while receiving Yeztugo for PrEP must transition to a complete HIV treatment regimen.

Clinical Criteria

When a drug is being reviewed for coverage under a member's medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

Yeztugo (lenacapavir)

Initial requests for Yeztugo (lenacapavir) may be approved if the following criteria are met:

I. Individual weighs at least 35 kg; **AND**
II. Individual is using for pre-exposure prophylaxis (PrEP) of human immunodeficiency (HIV) infection; **AND**
III. Individual will undergo HIV testing immediately (within one week) prior to initiating therapy to verify HIV negative status.

Continuation requests for Yeztugo (lenacapavir) may be approved if the following criteria are met:

I. Individual is using for pre-exposure prophylaxis (PrEP) of human immunodeficiency (HIV) infection; **AND**
II. Individual is undergoing HIV testing immediately (within one week) prior to each Yeztugo injection to verify HIV negative status.

Yeztugo (lenacapavir) may not be approved for the following:

I. Individual who is HIV positive or whose HIV status is unknown; **OR**
II. In combination with another agent for HIV treatment or prophylaxis; **OR**
III. When the above criteria are not met and for all other indications.

Approval Duration:
Oral: 2 months
Injectable: 1 year

Quantity Limits

Yeztugo (lenacapavir) Quantity Limits

Drug	Limit
Yeztugo (lenacapavir) 300 mg	1 bottle (4 tablets) per one time fill
Yeztugo (lenacapavir) 463.5 mg/1.5 mL	1 kit (2 vials) per 24 weeks
Override Criteria	
If there is an anticipated delayed injection of Yeztugo and the bridge tablets will be started within two weeks of the missed injection, may approve 1 tablet per week for 2 months, maximum of 3 approvals (6 months).	

Coding

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

HCPCS

J0738	Injection, lenacapavir, 1 mg, FDA-approved prescription, only for use as HIV pre-exposure prophylaxis (not for use as treatment for HIV)
J0752	Oral, lenacapavir, 300 mg, FDA-approved prescription, only for use as HIV pre-exposure prophylaxis (not for use as treatment for HIV)

ICD-10 Diagnosis

Z11.4	Encounter for screening for human immunodeficiency virus [HIV]
Z29.81	Encounter for HIV pre-exposure prophylaxis

Document History

New: 8/15/2025
Document History:

- 09/09/2025 - Coding Update: Removed HCPCS C9399, J0799 effective 9/30/25 and added J0738, J0752 effective 10/1/25.
- 8/15/2025 – Annual Review: New clinical criteria and quantity limit for Yeztugo. Coding Reviewed: Added HCPCS NOC C9399, J0799, and ICD-10-CM Z11.4, Z29.81.

References

1. Centers for Disease Control and Prevention: US Public Health Service: Preexposure prophylaxis for the prevention of HIV infection in the United States—2021 Update: a clinical practice guideline. December 2021. Available at: https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2021.pdf. Accessed: September 4, 2025.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. http://dailymed.nlm.nih.gov/dailymed/about.cfm. Accessed: September 4, 2025.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc. Updated periodically.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.